Compare Huntington Ingalls Industries Inc (HII) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Ingalls Industries Inc vs Repligen Corporation Common Stock — how do they compare? Huntington Ingalls Industries Inc trades at $265.15 (market cap $10.16B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Huntington Ingalls Industries Inc and Repligen Corporation Common Stock are close in size by market cap, and Huntington Ingalls Industries Inc pays a 2.14% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Huntington Ingalls Industries Inc for 30 Days and Repligen Corporation Common Stock for 0 Days on average.
| HII | RGEN | |
|---|---|---|
Market Cap | $10.16B | $11.14B |
Volume | 503,029 | 1,259,263 |
Sector | Industrials | Health |
52-Week High | $453.73 | $194.57 |
52-Week Low | $257.05 | $102.87 |
Typical Hold Time | 30 Days | 0 Days |
Enterprise Value | $13.08B | $11.02B |
Dividend Yield | 2.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HII trades at $257.84, down 2.34% today, amid a bearish technical signal but strong fundamentals. The company demonstrates consistent earnings beats, with Q2 2026 EPS of $5.27 exceeding expectations by 39%. Recent contract wins, including a $5.1 billion aircraft carrier overhaul and 10 unmanned vessel orders, bolster its $57.3 billion backlog. Valuation metrics appear attractive with a P/E of 15.36 and P/S of 0.77.
The investment case balances strong defense sector positioning against near-term technical weakness. Analyst consensus targets $357.00, implying 38% upside, with 41% buy ratings. Key risks include execution on large contracts and defense budget fluctuations. The current price near support at $258 presents a potential entry point for long-term investors.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Huntington Ingalls Industries Inc
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
